Sometimes, diabetes science confuses me.
Let’s take the news of an emerging class of diabetes drugs (type 2-focused) that apparently do something we’ve always thought was bad… but it’s actually not.
Sodium-glucose transporter (SGLT-2) inhibitors increase insulin production and effectiveness and stop the liver from producing too much glucose. Basically, they work by spilling glucose over into the urine which leads to less sugar in your bloodstream. The effect: lower BGs and A1Cs.
Sure, it…
Read more »
By
WilD on
March 10, 2012
Most of us come to expect certain things… like feeling your lows and fitting into your pants! So why do those things sometimes change? That’s what we’re covering in this week’s diabetes advice column, Ask D’Mine, hosted by veteran type 1, diabetes author and community educator Wil Dubois.
{Need help navigating life with diabetes? Email us at AskDMine@diabetesmine.com}
Kayla from Nebraska, type 1, writes: I recently noticed that I am not experiencing noticeable signs…
Read more »
The world of type 2 diabetes drugs is wacky indeed. While Amylin’s long-acting version of Byetta — called Bydureon and predicted by many experts to become a blockbuster — is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred.
The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that…
Read more »
Considering what I am about to write, I feel a little guilty about the post headline here. But these sensational headlines are just the point: the media is abuzz the last few days with the possibility that Lantus insulin “may be linked” to cancer.
The rumors started late last week, when the media got wind that a prominent diabetes researcher forecasted that an “earthquake” event was about to hit that would compromise the safety profile…
Read more »
By
AmyT on
November 4, 2008
Again, Januvia is one of the most searched-for terms on this site — which is interesting, because it’s an oral drug for controlling Type 2 diabetes with which I have no personal experience. But there’s a “perfect storm” surrounding Januvia that encapsulates many of the controversial themes running through diabetes care:
Show Me the Money
If you recall, Januvia is an oral DPP-4 inhibitor that lowers blood sugar by inhibiting glucagon release, versus the GLP-1…
Read more »
